New drug aims to stop deadly complication in leukemia therapy
NCT ID NCT07597941
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether the drug Lisaftoclax can prevent differentiation syndrome (DS), a severe and sometimes life-threatening side effect, in people with acute promyelocytic leukemia (APL) who are receiving standard treatment. About 60 participants aged 16 and older will take Lisaftoclax alongside their usual therapy. The goal is to see if this approach lowers the rate of DS and improves safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.